Real-world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program.
Liraglutide 3.0 mg
SaxendaCare®
obesity
persistence
Journal
Obesity science & practice
ISSN: 2055-2238
Titre abrégé: Obes Sci Pract
Pays: United States
ID NLM: 101675151
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
04
12
2019
revised:
10
03
2020
accepted:
21
03
2020
entrez:
3
9
2020
pubmed:
3
9
2020
medline:
3
9
2020
Statut:
epublish
Résumé
Weight management medications can significantly increase patients' chances of achieving a clinically meaningful weight loss if patients persist with treatment. This retrospective observational study of de-identified medical records of 311 patients is the first real-world study examining persistence with liraglutide 3.0 mg in Canada, and also investigates associations between the SaxendaCare® patient support program and persistence and weight loss. Overall persistence was assessed, as well as associations of enrollment in SaxendaCare®, persistence and weight loss. Overall mean (standard deviation) persistence with liraglutide 3.0 mg was 6.3 (4.1) months, and 67.5% ( These findings suggest that, in clinical settings, persistence with liraglutide 3.0 mg can exceed 6 months, and that enrolling in SaxendaCare® may be associated with comparatively longer persistence and, regardless of persistence, greater weight loss.
Identifiants
pubmed: 32874673
doi: 10.1002/osp4.419
pii: OSP4419
pmc: PMC7448157
doi:
Types de publication
Journal Article
Langues
eng
Pagination
382-389Informations de copyright
© 2020 The Authors. Obesity Science & Practice published by World Obesity and The Obesity Society and John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
Sean Wharton: owner and medical director of the Wharton Medical Clinic (WMC), and internal medicine specialist at Hamilton Health Sciences. He has previously received research grants from Canadian Institutes of Health Research (CIHR) and Mitacs; previous funding from Novo Nordisk, Bausch Health, Eli Lilly, Janssen and AstraZeneca for advisory work.Christiane Lundegaard Haase: employee of Novo Nordisk A/S.Elham Kamran: research coordinator at WMC, and a member of this working group.Aiden Liu: employee of Novo Nordisk Canada Inc.Johanna Mancini: employee of IQVIA Solutions Canada Inc.Drew Neish: employee of IQVIA Solutions Canada Inc.Arash Pakseresht: employee of Novo Nordisk A/S.G. Sarah Power: employee of IQVIA Solutions Canada Inc.Rebecca A.G. Christensen: employee of WMC at the time of this study.
Références
CMAJ. 2007 Apr 10;176(8):S1-13
pubmed: 17420481
Int J Obes (Lond). 2013 Nov;37(11):1443-51
pubmed: 23812094
Obes Sci Pract. 2017 Mar;3(1):3-14
pubmed: 28392927
N Engl J Med. 2015 Jul 2;373(1):11-22
pubmed: 26132939
Adv Nutr. 2017 May 15;8(3):449-462
pubmed: 28507010
JAMA. 2015 Aug 18;314(7):687-99
pubmed: 26284720
Appetite. 2012 Apr;58(2):432-7
pubmed: 22155072
Diabetes Obes Metab. 2018 Mar;20(3):734-739
pubmed: 28950422
Int J Obes (Lond). 2016 Aug;40(8):1310-9
pubmed: 27005405
Diabetes Res Clin Pract. 2018 Sep;143:348-356
pubmed: 30009937
Obes Sci Pract. 2017 Nov 21;3(4):425-433
pubmed: 29259801
J Gen Intern Med. 2018 Feb;33(2):136-138
pubmed: 29204970
J Med Internet Res. 2009 Jan 13;11(1):e1
pubmed: 19141433
Pharmacotherapy. 2013 Dec;33(12):1299-307
pubmed: 24019195
Int J Obes (Lond). 2007 Oct;31(10):1567-70
pubmed: 17420781
Value Health. 2017 Sep;20(8):1003-1008
pubmed: 28964430
Obesity (Silver Spring). 2019 Jun;27(6):917-924
pubmed: 31062937
N Engl J Med. 2016 Jul 28;375(4):311-22
pubmed: 27295427
Diabetes Obes Metab. 2019 Jun;21(6):1498-1501
pubmed: 30768836